Replies to post #120335 on Biotech Values

[bladerunner1717]

re: CLDX

This may not be an insignificant hire, IMO


Celldex Expands Senior Management Team with Appointment of Dr. Ronald A. Pepin, Senior Vice President and Chief Business Officer
businesswire



Companies:
Celldex Therapeutics, Inc.

Related Quotes
Symbol Price Change
CLDX 3.66 +0.11
Chart for Celldex Therapeutics, Inc
Press Release Source: Celldex Therapeutics, Inc. On Wednesday July 6, 2011, 8:00 am EDT

NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (Nasdaq:CLDX - News) today announced the appointment of Ronald A. Pepin, Ph.D. to Senior Vice President and Chief Business Officer, effective immediately. Dr. Pepin brings to Celldex more than 20 years of business development and senior leadership experience in the biotechnology and pharmaceutical industries.

“We are very excited to have Ron join us at Celldex,” said Anthony S. Marucci, Celldex’s President and CEO. “Our management team worked closely with Ron while we were together at Medarex and we saw first-hand his business development expertise as evidenced by a series of successful global drug development and commercialization agreements. His experience will be extremely valuable to Celldex as we continue advancing our portfolio of mid- and late-stage oncology products.”

Dr. Pepin most recently served as Vice President at Shire Pharmaceuticals. Previously, from 2000-2009, he was Senior Vice President, Business Development at Medarex, Inc., where he was instrumental in establishing more than forty collaborations with global biopharmaceutical companies. Among his successes were co-development and co-marketing agreements with Merck, Ono Pharmaceuticals and Bristol-Myers Squibb, the latter of which led to the successful development of Yervoy™ (ipilimumab). During his Medarex tenure, he established long term collaborations with leading companies including Genentech, Novartis, Amgen, Johnson & Johnson, Pfizer, Abbott and others.

“I am pleased to be joining my former colleagues at such an exciting time for Celldex,” commented Dr. Pepin. “The Company’s antibody-based cancer immunotherapy pipeline is among the most promising in the industry today. I look forward to working with the Celldex management team in realizing the fullest potential from each of their product candidates.”

Earlier in his career, Dr. Pepin was Executive Director of External Science and Technology at Bristol-Myers Squibb. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Biology from Georgetown University.


Bladerunner